Skip to main content
S&P 5007,592.40-0.58%DOW52,022.21-0.68%NASDAQ26,091.78-0.62%BTC$77,165.00-1.57%ETH$2,463.62-0.62%GOLD$4,372.10-1.99%OIL$102.07+6.27%
Smart Investors Daily
VK

NASDAQ · VKTX

Viking Therapeutics, Inc.

Healthcare · Biotechnology

$32.70

Down-$0.31 (-0.95%)

Updated Sep 10, 2026, 6:22 PM

SID Score

4.3/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.21B
P/E ratio
-17.61
Dividend yield
0.00%
52-week range
$27.16 – $42.79
Volume
2.04M
Avg. volume
4.44M

Price performance

VKTX price history

1M range · 20 trading sessions · Daily adjusted prices

VKTX closed at $32.70 after 20 trading sessions, down 3.88% for the selected period.

Last close
$32.70
Period change
-3.88%
Period low
$32.16
Period high
$35.98
Daily close
View OHLC price history
VKTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$33.36$34.60$32.59$32.702.04M
Sep 8, 2026$34.63$34.81$33.53$33.681.87M
Sep 4, 2026$33.75$34.95$33.56$34.871.4M
Sep 3, 2026$34.00$34.45$33.68$33.981.39M
Sep 2, 2026$33.67$34.75$32.7708$33.501.57M
Sep 1, 2026$32.61$33.71$32.38$33.671.68M
Aug 31, 2026$31.77$32.98$31.70$32.781.78M
Aug 28, 2026$33.75$33.86$31.98$32.162.38M
Aug 27, 2026$34.33$34.39$33.15$33.862.21M
Aug 26, 2026$34.09$34.75$33.802$34.381.14M
Aug 25, 2026$33.67$34.994$33.43$34.172.1M
Aug 24, 2026$33.75$33.765$32.61$33.231.75M
Aug 21, 2026$34.79$34.98$33.47$33.891.5M
Aug 20, 2026$35.79$35.79$33.9618$34.361.67M
Aug 19, 2026$34.10$36.26$33.8301$35.982.69M
Aug 18, 2026$33.42$33.94$33.00$33.371.19M
Aug 17, 2026$33.13$33.83$32.76$33.631.53M
Aug 14, 2026$32.56$33.28$32.3346$33.191.18M
Aug 13, 2026$33.86$33.9712$32.53$32.943.71M
Aug 12, 2026$34.07$34.735$33.50$34.021.47M

Latest VKTX news

The latest Smart Investors Daily articles mentioning VKTX.

Stock researchCompany · Overview

VKTX research

Overview

Company profile and research snapshot.

Company profile

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$104.67
Implied upside
—
Analysts
—
VKTX recent ratings
DateFirmRatingTarget
Aug 11, 2026JP MorganOverweight—
Jul 30, 2026Canaccord GenuityBuy—
May 28, 2026Lake StreetBuy—
Apr 30, 2026Cantor FitzgeraldOverweight—
Mar 23, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run?

Viking Therapeutics stock has delivered a very strong 5 year run, yet current valuation checks suggest the shares are priced at the richer end of the spectrum rather than as a clear bargain. Around 411.0% total return over 5 years highlights how much optimism has already been reflected in Viking Therapeutics shares. Progress of obesity candidate VK2735 and other metabolic programs, supported by a reported US$502 million cash position, can support high expectations, while any setback in...

Yahoo · Sep 2, 2026

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in September.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By